Cardiovascular Disease, Statins, and HIV.

Area of Science:

• Immunology
• Infectious Diseases
• Cardiology

Background:

• HIV infection leads to immune dysfunction, chronic inflammation, and heightened immune activation.
• This persistent inflammation increases the risk of serious non-AIDS-defining comorbidities, including cardiovascular disease, even with effective antiretroviral therapy.
• Statins possess significant immunomodulatory properties.

Purpose of the Study:

• To review the mechanisms of increased inflammation in HIV infection.
• To examine the contribution of this inflammation to cardiovascular disease risk in HIV patients.
• To explore the potential benefits of statins in managing comorbidities in this population.

Main Methods:

• Literature review focusing on HIV pathogenesis, inflammation, and cardiovascular risk.
• Review of studies on the immunomodulatory effects of statins.
• Analysis of how statins may impact comorbidities in HIV-infected individuals.

Main Results:

• Chronic HIV infection is characterized by persistent immune activation and inflammation.
• Inflammation is a key driver of cardiovascular disease and other comorbidities in HIV patients.
• Statins demonstrate broad immunomodulatory effects that could reduce inflammation and associated risks.

Conclusions:

• Understanding HIV-associated inflammation is crucial for managing comorbidities.
• Statins show promise in attenuating cardiovascular disease and other non-AIDS-defining comorbidities in HIV patients.
• Further research into statin use in HIV management is warranted.